I 
113TH CONGRESS 
2D SESSION 
H. R. 4494 
To launch a national strategy to support regenerative medicine through fund-
ing for research and commercial development of regenerative medicine 
products and development of a regulatory environment that enables rapid 
approval of safe and effective products, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 28, 2014 
Ms. DEGETTE (for herself and Mr. PAULSEN) introduced the following bill; 
which was referred to the Committee on Energy and Commerce 
A BILL 
To launch a national strategy to support regenerative medi-
cine through funding for research and commercial devel-
opment of regenerative medicine products and develop-
ment of a regulatory environment that enables rapid 
approval of safe and effective products, and for other 
purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE; TABLE OF CONTENTS. 
(a) SHORT TITLE.—This Act may be cited as the 
‘‘Regenerative Medicine Promotion Act of 2014’’. 
VerDate Mar 15 2010 
02:09 Apr 29, 2014
Jkt 039200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H4494.IH
H4494
smartinez on DSK6TPTVN1PROD with BILLS
(b) TABLE OF CONTENTS.—The table of contents of 
this Act is as follows: 
Sec. 1. Short title; table of contents. 
Sec. 2. Findings. 
Sec. 3. Report on ongoing Federal programs and activities regarding regenera-
tive medicine. 
Sec. 4. Establishment of Regenerative Medicine Coordinating Council. 
Sec. 5. Grants for basic or preclinical research into regenerative medicine. 
Sec. 6. Grants for development of drugs, biological products, medical devices, 
and biomaterials for use in regenerative medicine. 
Sec. 7. Supporting innovation in regenerative medicine through cures accelera-
tion network. 
Sec. 8. Funding for Food and Drug Administration research. 
SEC. 2. FINDINGS. 
Congress finds the following: 
(1) Regenerative medicine has the potential to 
treat many chronic diseases, promote economic 
growth, and reduce health care spending in the 
United States. 
(2) Regenerative medicine products have al-
ready successfully treated numerous health condi-
tions, and have the potential to provide cures, treat-
ments, and diagnostics for a range of diseases and 
disabilities including diabetes, spinal cord injury, 
heart disease, stroke, and various forms of cancer. 
(3) A United States national strategy on regen-
erative medicine is critical to ensure that this tech-
nology fulfills its potential to cure and treat diseases 
and disabilities, reduce overall health spending, and 
promote economic growth. 
VerDate Mar 15 2010 
02:09 Apr 29, 2014
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H4494.IH
H4494
smartinez on DSK6TPTVN1PROD with BILLS
(4) The Department of Defense has stated that 
regenerative medicine has the potential to treat 
many battlefield injuries such as burns, that it has 
the potential to heal wounds without scarring, and 
that it has the potential to be used for traumatic 
brain injury and other forms of trauma, craniofacial 
reconstruction, limb reconstruction, regeneration, 
and transplantation. 
(5) The Department of Health and Human 
Services and the Multi-Agency Tissue Engineering 
Science Interagency Working Group have endorsed a 
national initiative to support research and product 
development in regenerative medicine. 
(6) The Department of Health and Human 
Services has said the potential benefits of regenera-
tive medicine in improved health care and economic 
savings are enormous. States that have invested in 
regenerative medicine have experienced economic 
growth and see future growth potential, including an 
increase in biotech employment, payroll increases, 
and proportional impacts on tax receipts. 
VerDate Mar 15 2010 
02:09 Apr 29, 2014
Jkt 039200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H4494.IH
H4494
smartinez on DSK6TPTVN1PROD with BILLS
SEC. 3. REPORT ON ONGOING FEDERAL PROGRAMS AND 
ACTIVITIES 
REGARDING 
REGENERATIVE 
MEDICINE. 
Not later than 180 days after the date of the enact-
ment of this Act, the Comptroller General of the United 
States shall provide for the completion, and submission 
to the Congress, of a report identifying all ongoing Federal 
programs and activities regarding regenerative medicine. 
SEC. 4. ESTABLISHMENT OF REGENERATIVE MEDICINE CO-
ORDINATING COUNCIL. 
(a) ESTABLISHMENT.—The Secretary of Health and 
Human Services shall establish, within six months of the 
enactment of this Act, in the Office of the Secretary, a 
Regenerative Medicine Coordinating Council (in this sec-
tion referred to as the ‘‘Council’’). 
(b) COMPOSITION.—The Council shall be composed 
of the following: 
(1) The Secretary of Commerce. 
(2) The Secretary of Defense. 
(3) The Secretary of Health and Human Serv-
ices. 
(4) The Secretary of the Treasury. 
(5) The Secretary of Veterans Affairs. 
(6) The Administrator of the Agency for 
Healthcare Research and Quality. 
VerDate Mar 15 2010 
02:09 Apr 29, 2014
Jkt 039200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H4494.IH
H4494
smartinez on DSK6TPTVN1PROD with BILLS